Togni M, Maestroni G
IST CANTONALE PATOL,CTR EXPT PATHOL,CH-6604 LOCARNO,SWITZERLAND.
Int J Oncol. 1996 Aug;9(2):313-8. doi: 10.3892/ijo.9.2.313.
We demonstrated that adrenergic agents may affect hematopoiesis via high and low affinity al-adrenergic receptors (alpha 1-ARs) present on bone marrow cells. Here we show that the high affinity, alpha 1-AR is present on Mac1(-) B220(+)sIgM(-) (pre-B) cells. The low affinity alpha 1-AR seems to be present on Mac1(+) B220(-) cells. Noradrenaline administration in mice rescued hematopoiesis from the toxic effect of carboplatin or X-rays sublethal irradiation. The protection was reflected by higher leukocyte and platelets counts as well as by increased bone marrow granulocyte/macrophage colony-forming units (GM-CFU). At its most effective dose (3 mg/kg, s.c.), noradrenaline protected 77% of the mice injected i.v. with 200 mg/kg of carboplatin (LD 100:170 mg/kg). The contemporary administration of the alpha 1-AR antagonist prazosin brought the percent of surviving mice down to 30% indicating that alpha 1-ARs mediated most of the noradrenaline-induced hematopoietic rescue. In vitro, noradrenaline (1 mu M) rescued GM-CFU in unseparated bone marrow cells containing the adherent population expressing the high affinity alpha 1-AR. Consistently, the hematopoietic rescue was counteracted by low concentrations (0.1 nM-10 nM) of the alpha 1-antagonist prazosin. Our findings describe a novel mechanism of hematopoietic regulation and might find application in preventing the myeloablative effect of anticancer treatments.
我们证明,肾上腺素能药物可能通过骨髓细胞上存在的高亲和力和低亲和力α1 - 肾上腺素能受体(α1-ARs)影响造血作用。在此我们表明,高亲和力α1-AR存在于Mac1(-) B220(+)sIgM(-)(前B)细胞上。低亲和力α1-AR似乎存在于Mac1(+) B220(-)细胞上。给小鼠注射去甲肾上腺素可使造血作用从卡铂或X射线亚致死照射的毒性作用中恢复。这种保护作用表现为白细胞和血小板计数升高,以及骨髓粒细胞/巨噬细胞集落形成单位(GM-CFU)增加。在其最有效剂量(3 mg/kg,皮下注射)时,去甲肾上腺素保护了77%静脉注射200 mg/kg卡铂(半数致死剂量:170 mg/kg)的小鼠。同时给予α1-AR拮抗剂哌唑嗪可使存活小鼠的百分比降至30%,这表明α1-AR介导了大部分去甲肾上腺素诱导的造血恢复。在体外,去甲肾上腺素(1 μM)可使未分离的骨髓细胞中的GM-CFU恢复,这些骨髓细胞中含有表达高亲和力α1-AR的贴壁细胞群。同样,低浓度(0.1 nM - 10 nM)的α1-拮抗剂哌唑嗪可抵消造血恢复作用。我们的研究结果描述了一种新的造血调节机制,可能在预防抗癌治疗的骨髓消融作用中得到应用。